ViiV Healthcare Ltd and Shionogi & Co., Ltd. Sunday announced an agreement revising their integrase inhibitor relationship, for ViiV to acquire the exclusive global rights to the Shionogi-ViiV Healthcare LLC joint venture assets. Shionogi will receive ongoing royalty and dividend stream as well as 10 percent equity in ViiV Healthcare.
ViiV Healthcare is a global specialist HIV company, established in November 2009 byGlaxoSmithKline (GSK,GSK.L) and Pfizer Inc. (PFE).
The assets include the investigational medicine dolutegravir and some early stage integrase inhibitor compounds.
Isao Teshirogi, CEO of Shionogi, said, "The new deal perfectly aligns with the strategic goals and capabilities of both companies. Shionogi are able to secure a continued revenue stream from the integrase inhibitor portfolio as well as a stake in ViiV Healthcare itself..."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.